GlassScriptPhysician profile
James A Geraghty
NPI 1417928128
$3,958.73
in general payments reported to CMS, 2019-2025
31 companies · $279 in 2025
The $279 reported for 2025 was less than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $344 · 2020: $1,466 · 2021: $341 · 2022: $625 · 2023: $326 · 2024: $578 · 2025: $279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,182.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $1,270.10 | 2020 | |
| Inspire Medical Systems, INC. | $494.68 | 2019-2025 | Inspire |
| Optinose US, INC. | $334.94 | 2021-2023 | |
| Regeneron Healthcare Solutions, INC. | $268.77 | 2021-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $260.85 | 2020-2024 | Cuvitru, Eohilia |
| Genzyme Corporation | $232.71 | 2019-2024 | |
| Intersect Ent, INC. | $133.82 | 2020-2021 | |
| Csl Behring | $110.72 | 2019-2024 | Hizentra |
| Stryker Corporation | $109.90 | 2019-2025 | Clarifix Cryotherapy Device, Scopis Ent, Xpress Loprofile |
| Aerin Medical INC. | $96.29 | 2022 | |
| Acclarent, INC | $96.21 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $84.58 | 2019-2024 | Fasenra, Tezspire |
| Ethicon US, LLC | $58.79 | 2019 | |
| Karl Storz Endoscopy-America | $51.13 | 2020 | |
| Medtronic, INC. | $45.25 | 2023 | Propel |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phadia US INC. | $38.30 | 2022-2023 | Immunocap |
| Neurent Medical Limited | $36.73 | 2024 | Neuromark Device, Neuromark Radiofrequency Console |
| Biocryst US Sales Co., LLC | $26.90 | 2024 | Orladeyo |
| Pharming Healthcare, INC. | $24.56 | 2022 | |
| Amgen INC. | $20.94 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $19.80 | 2025 | |
| Shire North American Group INC | $17.16 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $16.91 | 2023 | Seglentis |
| Merck Sharp & Dohme LLC | $16.46 | 2021 | |
| Genentech USA, INC. | $15.23 | 2023 | Xolair |
| Smith+Nephew, INC. | $14.19 | 2024 | Tula |
| Integra Lifesciences Corporation | $13.15 | 2019 | |
| Alk-Abello, INC | $12.93 | 2019 | |
| Sanofi-Aventis U.S. LLC | $12.47 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $12.25 | 2022 | |
| Glaxosmithkline, LLC. | $12.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Geraghty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.